Clinical trial
A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma
NCT04892173 is registered in ClinicalTrials.gov with Johnson & Johnson Enterprise Innovation Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 10, 2021
- Completion date
- June 30, 2028
- Enrollment
- 500 (estimated)
- Sites
- 193
Conditions
As the registry lists them; a condition with its own page is linked.